TY - JOUR
T1 - International Experience in Therapeutic Value and Value-Based Pricing
T2 - A Rapid Review of the Literature
AU - Prieto-Pinto, Laura
AU - Garzón-Orjuela, Nathaly
AU - Lasalvia, Pieralessandro
AU - Castañeda-Cardona, Camilo
AU - Rosselli, Diego
N1 - Publisher Copyright:
© 2020 ISPOR–The professional society for health economics and outcomes research
PY - 2020/12
Y1 - 2020/12
N2 - Objectives: To characterize at a global level the concept of therapeutic value (TV) and describe the experience of value-based pricing (VBP) policies in 6 reference countries. Methods: We conducted a rapid review of the literature that addressed 2 exploratory research questions. A systematic and exhaustive search was carried out up to July 2018 in MEDLINE (Ovid), Embase, Scopus, and Web of Science. Results: The concepts of TV and VBP are related; value frameworks for medicines should include social preferences, comparative effectiveness, safety, adoption viability, social impact, high quality of evidence, severity of illness, and innovation. The added therapeutic value (ATV) is the manner of measuring the therapeutic advantages of new medicines compared with existing ones in terms of comparative effectiveness and safety. There are variations in the mechanisms of reimbursement and drug pricing regulation between the countries of study. Conclusion: In a VBP system it is essential to establish the TV and ATV of a new medicine. Although there are no methodological guidelines for the implementation of VBP policies, the process implies from the beginning the definition of TV categories that will be included in the drug pricing and reimbursement systems. Agreements between the pharmaceutical industry and governments have become a useful tool as a negotiating mechanism in most countries.
AB - Objectives: To characterize at a global level the concept of therapeutic value (TV) and describe the experience of value-based pricing (VBP) policies in 6 reference countries. Methods: We conducted a rapid review of the literature that addressed 2 exploratory research questions. A systematic and exhaustive search was carried out up to July 2018 in MEDLINE (Ovid), Embase, Scopus, and Web of Science. Results: The concepts of TV and VBP are related; value frameworks for medicines should include social preferences, comparative effectiveness, safety, adoption viability, social impact, high quality of evidence, severity of illness, and innovation. The added therapeutic value (ATV) is the manner of measuring the therapeutic advantages of new medicines compared with existing ones in terms of comparative effectiveness and safety. There are variations in the mechanisms of reimbursement and drug pricing regulation between the countries of study. Conclusion: In a VBP system it is essential to establish the TV and ATV of a new medicine. Although there are no methodological guidelines for the implementation of VBP policies, the process implies from the beginning the definition of TV categories that will be included in the drug pricing and reimbursement systems. Agreements between the pharmaceutical industry and governments have become a useful tool as a negotiating mechanism in most countries.
KW - Drug Evaluation Commission
KW - drug evaluation
KW - drug price
KW - national drug policy
KW - price negotiation
KW - therapeutic value
KW - value-based pricing
UR - http://www.scopus.com/inward/record.url?scp=85088051573&partnerID=8YFLogxK
U2 - 10.1016/j.vhri.2019.11.008
DO - 10.1016/j.vhri.2019.11.008
M3 - Article
C2 - 32688214
AN - SCOPUS:85088051573
SN - 2212-1099
VL - 23
SP - 37
EP - 48
JO - Value in Health Regional Issues
JF - Value in Health Regional Issues
ER -
